■严重性,症状,COVID-19的结果被认为与病毒如何进入宿主细胞密切相关。该过程涉及血管紧张素转换酶2(ACE2)和酪氨酸蛋白激酶受体UFO(AXL)受体的关键作用。然而,关于ACE2和AXL的循环水平及其在COVID-19中的意义的研究有限。
■71个未感染个体的对照组也包括在研究中。根据《2019年冠状病毒病指南》(第10版),358例COVID-19患者被分为非重症病例和重症病例。采用酶联免疫吸附试验(ELISA)检测COVID-19感染后不同时间点血清ACE2/AXL水平,包括第0-7、8-15、31-179天和>180天。使用iFlash3000化学发光免疫分析仪评估COVID-19患者相同间隔的血清SARS-CoV-2IgG/IgM抗体。受试者工作特征(ROC)曲线用于评估生物标志物的诊断价值,并探讨了实验室参数与疾病进展之间的关联.
■与未感染组相比,COVID-19组的ACE2和AXL水平降低,SARS-COV-2IgG水平升高。AXL(AUC=0.774)对COVID-19的预测能力强于ACE2。在感染后的第一周,只有AXL水平在重度组和非重度组之间有统计学差异.第一周后,两组的ACE2和AXL水平存在差异。此外,在严重的COVID-19病例中,血清ACE2,AXL,SARS-COV-2IgM水平在第8-15天达到峰值,然后下降,而血清SARS-COV-2IgG水平持续上升,在下降前31-180天达到峰值。此外,与未感染组相比,感染组180天后AXL水平持续下降,SARS-COV-2IgG水平持续升高.
■血清ACE2和AXL水平与COVID-19严重程度相关。然而,AXL还可以在感染后的第一周提供临床恶化的早期预警。AXL似乎是预测COVID-19进展的潜在分子标志物。
UNASSIGNED: The severity, symptoms, and outcome of COVID-19 is thought to be closely linked to how the virus enters host cells. This process involves the key roles of angiotensin-converting enzyme 2 (ACE2) and the Tyrosine protein kinase receptor UFO (AXL) receptors. However, there is limited research on the circulating levels of ACE2 and
AXL and their implications in COVID-19.
UNASSIGNED: A control group of 71 uninfected individuals was also included in the study. According to the Guidance for Corona Virus Disease 2019 (10th edition), a cohort of 358 COVID-19 patients were categorized into non-severe and severe cases. Serum ACE2/AXL levels in COVID-19 patients were detected by enzyme-linked immunosorbent assay (ELISA) at different time points post-COVID-19 infection, including days 0-7, 8-15, 31-179 and >180 days. Serum SARS-CoV-2 IgG/IgM antibodies in COVID-19 patients at the same intervals were assessed by using an iFlash 3000 Chemiluminescence Immunoassay Analyzer. The receiver operating characteristic (ROC) curves were used to assess the diagnostic value of the biological markers, and the association between laboratory parameters and illness progression were explored.
UNASSIGNED: Compared with the uninfected group, the levels of ACE2 and AXL in the COVID-19 group were decreased, and the SARS-COV-2 IgG level was increased.
AXL (AUC = 0.774) demonstrated a stronger predictive ability for COVID-19 than ACE2. In the first week after infection, only the level of AXL was statistically different between severe group and non-severe group. After first week, the levels of ACE2 and
AXL were different in two groups. Moreover, in severe COVID-19 cases, the serum ACE2, AXL, and SARS-COV-2 IgM levels reached a peak during days 8-15 before declining, whereas serum SARS-COV-2 IgG levels continued to rise, reaching a peak at day 31-180 days before decreasing. In addition, the AXL level continued to decrease and the SARS-COV-2 IgG level continued to increase in the infected group after 180 days compared to the uninfected group.
UNASSIGNED: The levels of serum ACE2 and
AXL correlate with COVID-19 severity. However, AXL can also provide early warning of clinical deterioration in the first week after infection.
AXL appears to be a superior potential molecular marker for predicting COVID-19 progression.